4594 — BrightPath Biotherapeutics Co Balance Sheet
0.000.00%
- ¥4bn
- ¥3bn
- ¥0m
Annual balance sheet for BrightPath Biotherapeutics Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 3,018 | 3,265 | 2,305 | 1,531 | 1,057 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.659 | 0.283 | 16.6 | 0.055 | 0.006 |
Total Other Current Assets | |||||
Total Current Assets | 3,328 | 3,651 | 2,696 | 1,651 | 1,181 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 97.2 | 48.2 | 24.9 | 0 | 0 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 3,475 | 3,749 | 2,771 | 1,701 | 1,230 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 173 | 156 | 185 | 76.6 | 191 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 239 | 212 | 240 | 134 | 251 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 3,235 | 3,538 | 2,531 | 1,568 | 979 |
Total Liabilities & Shareholders' Equity | 3,475 | 3,749 | 2,771 | 1,701 | 1,230 |
Total Common Shares Outstanding |